The main goal of the Council is to enhance efficiency, foster development, and coordinate scientific and production activities conducted within the Holding’s subsidiaries.

The meeting was attended by the leadership of the Holding and its subsidiaries, as well as deputy directors for science. The results of 2023 were reviewed in areas such as scientific research, production, personnel training, and more. Plans for activities in the subsidiaries for 2024 were also discussed.

Particular attention during the meeting was given to the following issues:

Improving research work in applied and fundamental sciences within the subsidiaries;

Enhancing the qualifications of specialists working in the field of biological safety;

Systematizing the implementation and commercialization of scientific results (new technologies, developments, and products);

Expanding the range and volume of immunobiological products (vaccines, test systems, etc.) produced by subsidiaries to combat especially dangerous infections;

Upgrading the infrastructure of subsidiaries, equipping them with modern scientific equipment and instruments;

Strengthening international cooperation to develop science and technology, ensuring society’s needs for biopharmaceutical products are met.

At the conclusion of the meeting, the Council Chairman, Yergali Abdurayimov, assigned specific tasks to the Council members to ensure biological safety and advance scientific research and production in 2024.